Day: June 24, 2021

The International Action Centre issues the following statement on the recent judgement of the ECOWAS Court of Justice:

COURT RECONFIRMS ALEX SAAB DETENTION ILLEGAL

NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) — In its judgment delivered on 15 March 2021, the ECOWAS Court of Justice declared illegal the arrest and detention of Venezuelan diplomat Alex Nain Saab Moran, ordered his release from further custody, quashed the extradition proceedings against him to the United States and awarded him $200,000 reparation for the violations of his human rights by Cape Verde.

On 15 April, the Government of Cape Verde filed two motions praying the ECOWAS Court to set aside the Judgment. Both motions were vigorously opposed by the defence team of Alex Saab and in today’s decision, which followed a hearing on 31 May, the ECOWAS Court confirmed:

(i) There was no miscalculation of Time Zones when considering when the Interpol Red Notice was received by the Republic of Cape Verde and it had no bearing on the illegality of the arrest and subsequent detention, and
(ii) It is competent in terms of jurisdiction to rule on the matter.

The Defence Team notes that today’s decisions represent the end of the ECOWAS Court Process, and the Republic of Cape Verde has no more excuses to try and justify its non-compliance with the binding decisions of the ECOWAS Court.

Ambassador Saab’s family would like to express its gratitude to the Honourable ECOWAS Court for its steadfast application of law and asks that the Republic of Cape Verde abide by its international obligations and immediately release Alex Saab and end the vindictive extradition process against him.

Alex Saab’s Lead ECOWAS Counsel, Femi Falana SAN, said, “I am delighted that in dismissing Cape Verde’s applications, the Honourable Court has underlined that its decision of 15 March in terms of the illegality of Ambassador Saab’s detention must be respected by Cape Verde. The Defence Team now calls upon the competent authorities of Cape Verde to comply with the ECOWAS Court’s decision, immediately release Alex Saab and end the politically motivated extradition.”

Dr Jose Manuel Pinto Monteiro, Alex Saab’s lead Cape Verde attorney, commented, “Cape Verde is known as a nation which respects its international obligations and the rule of law. I join my colleague Mr Falana in calling upon the Cape Verde authorities to bring an immediate end to the illegal detention of Ambassador Saab, release him and permit him to travel freely to Venezuela.”

MEDIA Contact:
Sara Flounders
International Action Center
https://www.iacenter.org
E-mail: iacenter@iacenter.org
Tel: +1 212-633-6646

Top liver disease conference showcases positive clinical data from Yaqrit’s technologies

Results from two trials presented at EASL¹ International Liver Conference 2021 show benefits for patients with liver failure and those with advanced cirrhosis

London, UK, 24 June, 2021 – New treatments for liver disease patients have been given top billing at this week’s International Liver Congress (ILC), one of the biggest global meetings for liver doctors and researchers, including technologies being developed by Yaqrit Discovery Ltd (‘Yaqrit’ or the ‘Company’), a UK life sciences company developing treatments for patients with cirrhosis and its complications, an area of global unmet medical need.

Dialive™ is an ICU device for patients suffering from acute-on-chronic liver failure

In the first of two presentations on Yaqrit’s Dialive technology, trial data showed that patients had statistically significantly better outcomes when treated with Dialive compared to patients in a control group.

Twice as many patients in the group treated with Dialive resolved from acute on chronic liver failure grades 1, 2 or 3 to ACLF grade 0. The treated group also resolved more quickly than the standard of care group.

Dr Banwari Agarwal, Chief Investigator and presenter of the data at the ILC, commented: “To see patients with ACLF grades 1, 2 and 3a resolving to ACLF 0 at twice the rate with Dialive treatment compared to those in the control group, is simply a remarkable outcome. Furthermore, this improvement was achieved with no treatment-related safety issues, which will be vital as the product enters pivotal studies in a larger population of patients.”

ACLF is a serious condition often treated in the hospital intensive care unit. Patients have a 28-day expected short term mortality rate that ranges from 20% to over 80%². Dialive is an ICU treatment based on the double filtration of blood-borne toxins and the replacement of damaged circulating albumin.

Carbalive™ is an orally-administered macroporous carbon bead solution to treat decompensated cirrhosis

Yaqrit’s second technology, Carbalive, is an adsorbent taken by mouth by patients with decompensated cirrhosis. Decompensated patients are usually hospitalised and at risk of deteriorating further to life-threatening ACLF.

Carbalive also met its primary endpoint of safety in a placebo-controlled clinical trial across Europe and in addition showed positive trends in markers of inflammation and gut health. These measures of gut health included those that signify a reduction in the translocation (leaking) of bacterial toxins out of the gut, an important factor in cirrhosis³.

Dr Jane McNaughton, a University College London hepatologist presenting the data at ILC, said “These findings in decompensated cirrhosis patients pave the way for the next stage of clinical development, which will be to evaluate Carbalive in dedicated efficacy studies and in higher risk patient populations.”

The EU Horizon 2020-supported clinical trials of Dialive and Carbalive were conducted in hospitals across Europe respectively by two academic-industrial consortia, ALIVER and CARBALIVE. Both technologies had previously strong preclinical data at University College London, where they had been invented and developed by Professor Rajiv Jalan and colleagues at the Liver Failure Group based at the Royal Free Hospital, London.

Professor Rajiv Jalan M.D., Professor of Hepatology at UCL, Yaqrit’s lead founder, said, “Carbalive’s design is based on many observations of the course of patients in liver decompensation and the damaging inflammation that results. It’s pleasing to see that not only has its safety been shown in this study but that there are encouraging signs of benefits to patients, which we hope will be confirmed in future trials.”

“The randomised controlled clinical trials conducted with two of Yaqrit’s development programmes product candidates yielded promising clinical results, and those obtained with Dialive exceeded our expectations”, said Daniel Green, CEO of Yaqrit. “We look forward to expanding our trials globally for both Carbalive and Dialive.”

At the International Liver Congress, Dr Agarwal’s presentation is:

Session: Global Session – 1997
Date/Time: 24 June 2021, 4 pm CEST
Abstract: A multi-centre, randomized controlled study, to evaluate the safety and performance of the DIALIVE Liver Dialysis Device in patients with Acute on Chronic Liver Failure (ACLF) versus standard of care (SOC)

At the International Liver Congress, Dr McNaughtan’s presentation is:

Session: PO-1045
Date/Time: 26 June 2021, 9.08 am CEST
Abstract: A Double Blind, Randomised, Placebo-Controlled Study To Assess Safety and Tolerability of Oral Enterosorbent Yaq-001 In Cirrhotic Patients (CARBALIVE Consortium)

At the International Liver Congress, Dr Bañares’s presentation is:

Session: OS-2060
Date/Time: 26 June 2021, 10.15 am CEST
Abstract: Pathophysiological basis of resolution of Acute-on-Chronic Liver Failure (ACLF) induced by the novel liver dialysis device, DIALIVE

About the ALIVER Consortium
The ALIVER consortium includes many of Europe’s leading experts in liver failure and the hospitals where they work, small and medium-sized enterprises (SMEs) and not-for-profit organisations, with 25 years of experimental research and data collection exploring extracorporeal liver support in liver failure. DIALIVE research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 733057.For more information visit www.aliver.info

About the CARBALIVE Consortium

Humans have nearly 10 trillion intestinal bacteria. This is the gut microbiome, which both plays an important role in human health and is the largest reservoir of antigens and bacterial products in the body. If the gut is damaged, as is the case in liver disease, the bacterial products can leak from the gut to the liver where they cause inflammation and injury. These changes happen in chronic liver disease and in cirrhosis. Gut microbes also play a role in the progression of fatty liver disease to advanced liver disease, and it is these challenges that the CARBALIVE consortium was established to address. The Carbalive consortium has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634579. For more information visit www.carbalive.eu

About Yaqrit Discovery Ltd

Yaqrit is a clinical stage life sciences company focused on developing innovative treatments for patients with advanced liver disease in areas of high unmet medical need. The Company was founded by internationally renowned hepatologist Professor Rajiv Jalan of UCL, who has three decades of clinical, academic and research experience in treating patients with chronic liver disease. The Company has developed a clinical stage pipeline led by three programs: Carbalive and Dialive, both of which have complete randomised controlled clinical trials, and TLR4 antagonists, the most advanced of which is being developed by Akaza Bioscience, a collaboration with Takeda. These programs are designed to address unmet medical needs across the advanced stages of chronic liver disease from medically stable patients with decompensated cirrhosis in the outpatient setting, to critically ill, hospitalised patients with acute-on-chronic liver failure. The application of the different therapeutic approaches to specific patient groups is based upon the Company’s deep understanding of the pathway and stratification of patients with chronic liver disease. For more information visit www.yaqrit.com

Contacts

For further information is also available at www.aliver.info and www.carbalive.eu

---

¹ EASL : European Association For The Study Of The Liver
² “The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. Arroyo et al JHEP 2020

³ Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update – Fukui et al Gut Liver 2020 https://pubmed.ncbi.nlm.nih.gov/33071239/

Capital will help accelerate JW Player’s growth and expand its already robust platform, empowering customers with independence and control in the Digital Video Economy

NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) — JW Player, the leading video software and data insights platform, today announced it has raised $100M in Series E funding from LLR Partners. The latest investment comes on the heels of record video streaming growth and strong profitability during the previous 12 months. With this financing, JW Player will accelerate product innovation to meet the rapidly changing demands of customers in today’s digital video environment, expand its global go-to-market footprint across sales, marketing and channel partnerships and continue to grow and invest in building a world-class team.

The funding round follows JW Player’s recent acquisition of VUALTO, a leading provider of live and on-demand video streaming and Digital Rights Management (DRM) solutions, that deepened the company’s offering to global broadcasters. In the days following the acquisition, JW Player has seen a material uptick and influx of sales and pipeline, especially in the LATAM and APAC regions.

Started as a hugely-popular open source video player, JW Player’s API-driven video platform now empowers hundreds of thousands of customers to independently control and operate their mobile, OTT and Web video applications at global scale. Importantly, JW Player includes unique data-driven services and knowledge so that customers can more effectively grow and engage their audiences and generate more incremental revenue from their video investments. In the last year alone, the company’s video streaming grew by nearly 200%, while its live streaming delivery increased by over 400%.

This financing arrives as the consumption of digital video continues its push to the mainstream. Video now comprises over 80% of all traffic on the internet, and according to JW Player data, people are consuming over two hours of digital video each day, a 40% increase since the beginning of 2020. As a result, a digital video strategy has become a ‘must have’ not only for media companies, but also for organizations of all types, including fitness, e-commerce, sports and e-learning businesses, among others. These organizations have a diverse range of needs, require a flexible video platform that allows them to engage with their audiences on the screens of their choice and demand a quantifiable ROI from their video investments. Given these dynamics, the addressable market is on target to grow from $14B today to $50B by 2027, a 20% CAGR.

“Video has entered into a golden age, and we now live in the Digital Video Economy. By combining our easy-to-use video platform technology with our unique consumption and contextual data insights, JW Player has a distinct advantage in helping customers grow their audiences, create world-class video experiences on any screen, and most importantly, generate more revenue,” said Dave Otten, CEO and co-founder of JW Player. “As we enter this next phase, we are thrilled to partner with LLR. LLR’s team brings decades of unmatched support and expertise in growing industry-changing software companies and will undoubtedly help us accelerate our success as we pursue this massive market opportunity together.”

“JW Player has been at the forefront of digital video innovation ever since founder Jeroen Wijering created YouTube’s original video player in 2008. Today, the company offers the most comprehensive technology, advertising and data analytics platform in the digital video ecosystem,” said David Reuter, Partner at LLR Partners. “We look forward to partnering with the JW Player team as they expand their platform and continue to elevate the way brands can host, stream and monetize video.”

About JW Player
JW Player is the leading video software and data insights platform that gives customers independence and control in today’s Digital Video Economy. Started in 2008 as a hugely popular open-source video player, JW Player ’s technology platform now powers digital video for hundreds of thousands of businesses, including half of the comScore top 50 sites in the US, leading broadcasters across EMEA, APAC and Latin America. Each month 1 billion viewers, or one third of all people on the Internet, consume video on JW Player’s technology across 2.7 billion devices, creating an unmatched and powerful consumption and contextual data graph that helps customers grow audiences and generate incremental video from digital video. The company is headquartered in New York, with offices in London and Eindhoven, visit http://www.jwplayer.com.

About LLR Partners
LLR Partners is a middle market private equity firm investing in technology and healthcare businesses. We collaborate with our portfolio companies to identify and execute on key growth initiatives and help create long-term value. Founded in 1999 and with more than $5 billion raised across six funds, LLR is a flexible provider of equity capital for growth, recapitalizations and buyouts. Learn more at https://www.llrpartners.com/.

Media Contacts:
Fatimah Nouilati
Scratch Marketing + Media for JW Player
fatimah@scratchmm.com

Kristy DelMuto
LLR Partners
kdelmuto@llrpartners.com

Shuttle to operate remotely over Rogers 5G network thanks to one of several key research partnerships

Waterloo, Ontario, June 24, 2021 (GLOBE NEWSWIRE) — The University of Waterloo is showcasing the operation of a driverless, autonomous shuttle research program that will transport students and staff around campus.

The demonstration of the shuttle, dubbed “WATonoBus” by the research team, is the first of its kind at a Canadian academic institution and marks a significant milestone in a multi-year initiative to demonstrate and integrate autonomous transportation onto the campus.

This milestone features another significant technological advancement, as the shuttle becomes the first in the country to operate remotely over Rogers 5G network, thanks to a Rogers partnership agreement with the University to advance 5G research in the Toronto-Waterloo tech-corridor. This past September, as Rogers expanded Canada’s largest and most reliable 5G network to reach more communities, it lit up the University’s 5G Smart Campus to support researchers developing 5G applications and use cases in a real-world setting.

The shuttle’s 5-stop, 2.7-kilometre journey around the Waterloo main campus, intersecting with the campus light rail transit stop, holds the potential to help reshape how entire communities move around their urban spaces.

“We are thrilled not only about WATonoBus, but what it represents,” said Feridun Hamdullahpur, president and vice-chancellor of the University of Waterloo. “By marrying transformational research, infrastructure and a network of industry and government partnerships, we are demonstrating that educational institutions will help shape the future – in this case, the convergence of public transportation and smart urban mobility.”

The driverless shuttle with remote takeover capability will showcase a full-system approach, developed entirely at the University of Waterloo, led by Professor Amir Khajepour and a team of over 20 researchers in the Mechatronic Vehicle Systems Laboratory. Funding support has been provided by federal and provincial partners, as well as contributions from Applanix, RoboSense AI, and Rogers to make WATonoBus a reality.

The technology includes an integrated on-board sensor system providing vehicle intelligence and control; a suite of front, rear and side cameras providing a 360-degree view; light detection and ranging (LIDAR) active remote sensing systems used for detecting objects; and a WATonoBus smartphone app to help passengers navigate the campus using the shuttle.

“Today’s demonstration represents over four years of work with support and collaboration with government and industry partners,” Khajepour said. “This is an exciting step forward in autonomous, driverless public transportation.”

And, for the first time in Canada, an autonomous shuttle will be operated entirely on a remote basis using a 5G network. The modem on board will communicate through the Rogers 5G network with a research lab-based control centre. In the control centre, a remote operator will monitor the WATonoBus operations, and take over control when needed to ensure safe movement.

“As real-world 5G use cases such as the WATonoBus begin to take shape, we are starting to see the potential of 5G come to life,” said Jorge Fernandes, Chief Technology Officer at Rogers Communications. “Smart cities and smart transportation solutions are poised to help make cities safer, more efficient and more environmentally friendly. This example of 5G innovation demonstrates the importance of fostering 5G research and development to help fuel industries and drive Canada’s digital economy forward. We are proud to help enable this important 5G moment as part of our partnership with the University of Waterloo.”

Since lighting up the campus with 5G last year, Rogers has added next generation network technology and capabilities that will enable more intelligent and complex use cases and applications, including 5G mmWave (28GHz) small cells on campus, both inside buildings and outdoors, providing ultra-low latency and high bandwidth to support a variety of  5G research projects underway at the University.

The demonstration is the latest step of a multi-year initiative that is creating a testbed to evaluate automated driving on campus. Future industry partnerships will add more elements of a smart city on campus, a living testbed for advanced research, product development and data collection.

Before commencing operation as a regular service, the driverless shuttle system requires approval from the Ontario Ministry of Transportation (MTO). Currently, the University of Waterloo is a registered participant in Ontario’s Automated Vehicle Pilot Program, which permits testing of driverless AVs on Ontario roads provided a safety operator is on board.

Federal and provincial funding for the WATonoBus project has been provided through the Canadian Foundation for Innovation, the Ontario Research Fund and the Natural Sciences and Engineering Research Council.

Rebecca Elming
University of Waterloo
226-929-7627
relming@uwaterloo.ca

SmartEdge Partner Program Winners Are Tech Data, SHI, Presidio, Atlantik, Arki, Data Equipment, Acromax, Rahi System India and Enthu Technology Sdn. Bhd.

IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM) offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware, today announced the winners of its SmartEdge™ Partner Program Awards. The awards were given at Lantronix’s 2021 SmartEdge Partner Summit held virtually on June 23, 2021.

Lantronix’s SmartEdge Partner Program Awards were given to winners in three categories: Distribution Partner, StrategicEdge Partner and Edge Partner covering three regions: North America, Europe/Middle East/Africa and Asia Pacific.

The winners are:
North America
North America Distributor Partner of the Year: Tech Data
North America StrategicEdge Partner of the Year: SHI
North America Edge Partner of the Year: Presidio

Europe/Middle East/Africa (EMEA)
EMEA Distributor Partner of the Year: Atlantik Elektronik
EMEA StrategicEdge Partner of the Year: Arki Technology
EMEA Edge Partner of the Year: Data Equipment

Asia Pacific (APAC)
APAC Distributor Partner of the Year: Acromax
APAC StrategicEdge Partner of the Year: Rahi Systems, India
APAC Edge Partner of the Year: Enthu Technology Sdn. Bhd.

“We are pleased to honor the SmartEdge Partner Program winners, all of which have exceeded our program requirements and expectations in driving sales and building long-term relationships with our mutual customers,” said Roger Holliday, VP of WW Sales at Lantronix.

SmartEdge Partner Program One-Year Anniversary

Lantronix celebrated the one-year anniversary of its new SmartEdge Partner Program in April 2021. “The Lantronix SmartEdge Partner Program has attracted the industry’s top channel partners,” said Jonathan Shipman, VP of Strategy at Lantronix. “With our SmartEdge Program, our channel partners offer Lantronix’s integrated offering of software, hardware and service solutions, providing their customers with everything they need to build robust, secure connectivity-based solutions.”

Lantronix Named to CRN Partner Program Guide

Lantronix’s SmartEdge Partner Program has been named to the industry’s leading partner program guide, the CRN Partner Program Guide. Published by CRN^®, a brand of The Channel Company, this annual guide provides a conclusive list of the most distinguished partner programs from leading technology companies that provide products and services through the IT Channel. The 2021 Partner Program Guide is online at www.CRN.com/PPG.

About the SmartEdge Partner Program

Lantronix’s SmartEdge™ Partner Program was designed to help Value-Added Resellers (VARs) and Systems Integrators (SIs) drive revenues by differentiating their offerings with Lantronix’s innovative Industrial Internet of Things (IoT), Remote Environment Management (REM), Out-of-Band Management (OOBM) and Mobility/Connectivity solutions.
For more information on the Lantronix SmartEdge Partner Program, visit www.lantronix.com/partners.

About Lantronix

Lantronix Inc. is a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM), offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware. Lantronix enables its customers to provide reliable and secure solutions while accelerating their time to market. Lantronix’s products and services dramatically simplify operations through the creation, development, deployment and management of customer projects at scale while providing quality, reliability and security.

With three decades of proven experience in creating robust IoT technologies and OOBM solutions, Lantronix is an innovator in enabling its customers to build new business models, leverage greater efficiencies and realize the possibilities of the Internet of Things. Lantronix’s solutions are deployed inside millions of machines at data centers, offices and remote sites serving a wide range of industries, including energy, agriculture, medical, security, manufacturing, distribution, transportation, retail, financial, environmental and government.

Lantronix is headquartered in Irvine, Calif. For more information, visit www.lantronix.com. Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Any statements set forth in this news release that are not entirely historical and factual in nature, including without limitation statements related to our solutions, technologies and products are forward-looking statements. These forward-looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; the impact of the COVID-19 outbreak on our employees, supply and distribution chains, and the global economy; cybersecurity risks; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, filed with the Securities and Exchange Commission (the “SEC”) on September 11, 2020, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. The forward-looking statements included in this release speak only as of the date hereof, and we do not undertake any obligation to update these forward-looking statements to reflect subsequent events or circumstances.

© 2021 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark, and EMG and ConsoleFlow are trademarks of Lantronix Inc. Other trademarks and trade names are those of their respective owners.

© 2021. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.

Lantronix Media Contact:
Gail Kathryn Miller
Corporate Marketing &
Communications Manager
media@lantronix.com
949-453-7158

Lantronix Analyst and Investor Contact:
Jeremy Whitaker
Chief Financial Officer
investors@lantronix.com
949-450-7241

Lantronix Sales:
sales@lantronix.com
Americas +1 (800) 422-7055 (US and Canada) or +1 949-453-3990
Europe, Middle East and Africa +31 (0)76 52 36 744
Asia Pacific + 852 3428-2338
China + 86 21-6237-8868
Japan +81 (0) 50-1354-6201
India +91 994-551-2488

ข้อตกลงใหม่ขยายขอบเขตการเข้าถึงทั่วโลกของ Conformis และนำระบบการผ่าตัดเปลี่ยนข้อเข่าเทียมเฉพาะผู้ป่วยไปสู่ตลาดที่ใหญ่ที่สุดในภูมิภาคเอเชียแปซิฟิก

BILLERICA, Mass., June 24, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) วันนี้ได้ประกาศการดำเนินการตามข้อตกลงเพื่อเข้าสู่ตลาดเอเชียแปซิฟิกผ่านความสัมพันธ์การจัดจำหน่ายแบบเอกสิทธิ์เฉพาะบุคคลกับ XR Medical Group (Hong Kong) Limited (XR Medical)

ภายใต้ข้อตกลงการจัดจำหน่าย XR Medical จะได้รับสิทธิพิเศษในการขาย ทำการตลาด และการจัดจำหน่ายระบบการผ่าตัดเปลี่ยนข้อเข่าเทียมแบบทั้งหมด iTotal^® CR & PS เฉพาะผู้ป่วยของ Conformis, อุปกรณ์สำหรับกระดูกสะบ้า iTotal^® CR & PS และระบบการผ่าตัดข้อเข่าเทียมชนิดบางส่วน iUni^® และ iDuo^® ผลิตภัณฑ์อื่นๆ เช่น ระบบสำหรับหัวเข่า Identity Imprint™ ที่ได้รับอนุมัติเมื่อไม่นานมานี้ของ Conformis และกลุ่มผลิตภัณฑ์สำหรับสะโพกของบริษัท ซึ่งอาจถูกเพิ่มเข้ามาในอนาคต

ทีมงานฝ่ายขายของ XR Medical จะมอบการขายและการสนับสนุนเฉพาะสำหรับสิ่งอำนวยความสะดวกระดับสูงใน Boao Lecheng International Medical Tourism Pilot Zone (เขตการค้าเสรีนำร่อง) ของไห่หนานในนามของ Conformis ภูมิภาคนี้เป็นศูนย์กลางการท่องเที่ยวทางการแพทย์ที่สำคัญสำหรับหลายสิบประเทศ

“ข้อตกลงการจัดจำหน่ายนี้เป็นอีกตัวอย่างหนึ่งของความคืบหน้าในขณะที่เราดำเนินกลยุทธ์การเติบโตโดยรวมของเรา เรามั่นใจว่ากลุ่มผลิตภัณฑ์ที่โดดเด่นของเราจะช่วยเร่งความเติบโตระดับสากลของ Conformis ได้ และเรายินดีที่จะเป็นพันธมิตรกับ XR Medical ซึ่งมีประวัติความสำเร็จที่น่าประทับใจในประเทศจีน” Mark Augusti ประธานและ CEO ของ Conformis กล่าว “สิ่งที่น่าสนใจเป็นพิเศษเกี่ยวกับ XR Medical คือประสิทธิภาพที่แข็งแกร่งในเขตการค้าเสรีนำร่อง ด้วยการเข้าถึงผู้ป่วยที่เข้ามาในภูมิภาคเพื่อรับการรักษา จะทำให้เกิดโอกาสที่จะแนะนำกลุ่มเป้าหมายที่กว้างขวางเกี่ยวกับประโยชน์ทางคลินิกของเทคโนโลยี Conformis เราเชื่อว่าการเริ่มต้นในเขตการค้าเสรีนำร่องทำให้เราอยู่ในตำแหน่งที่ดี และเราคาดว่าความสัมพันธ์นี้จะเป็นแบบอย่างสำหรับโอกาสในการขยายตัวในอนาคตในจีนแผ่นดินใหญ่”

เขตการค้าเสรีนำร่องตั้งอยู่บนไหหลำ ซึ่งเป็นเกาะขนาดใหญ่นอกชายฝั่งทางใต้ของจีน ซึ่งจัดตั้งขึ้นในปี 2019 เพื่อดึงดูดพลเมืองชาวจีนที่มีฐานะมั่งคั่งซึ่งอาจจะไปต่างประเทศเพื่อรับการดูแลทางการการแพทย์ เขตภูมิภาคนี้ของจีนได้พัฒนาสถานรักษาพยาบาลระดับสูงในจุดหมายปลายทางยอดนิยม ปัจจุบัน นักท่องเที่ยวทางการแพทย์จากหลายสิบประเทศ รวมทั้งในเอเชียตะวันออกเฉียงใต้ ได้รับอนุญาตให้เข้าพักที่ไหหลำได้ 30 วันโดยไม่ต้องขอวีซ่า

ตลาดโลกสำหรับการฟื้นฟูข้อเข่าคาดว่าจะมีมูลค่ามากกว่า 9 พันล้านดอลลาร์ จากทั้งหมดนี้ คาดว่าตลาดการฟื้นฟูข้อเข่าในภูมิภาคเอเชียแปซิฟิกในปัจจุบันจะมีมูลค่าเกิน 1.7 พันล้านดอลลาร์ Fortune Business Insights คาดการณ์อัตราการเติบโตสูงสำหรับการผ่าตัดเปลี่ยนข้อเข่าเทียมในภูมิภาคนี้ อันเนื่องมาจากจำนวนของอาการข้อเข่าเสื่อมที่เพิ่มขึ้น การท่องเที่ยวเชิงการแพทย์ที่เฟื่องฟู รายได้ที่เพิ่มขึ้น และโครงสร้างพื้นฐานด้านการดูแลสุขภาพที่ดีขึ้น

เกี่ยวกับ Conformis, Inc.

Conformis เป็นบริษัทเทคโนโลยีทางการแพทย์ที่ใช้แพลตฟอร์มเทคโนโลยี iFit^® Image-to-Implant® ที่เป็นกรรมสิทธิ์ เพื่อพัฒนา ผลิต และจำหน่ายการปลูกถ่ายและอุปกรณ์สำหรับข้อเข่าที่มีขนาดและรูปทรงแตกต่างกัน ซึ่งเราหมายความว่าเป็นส่วนบุคคล เฉพาะบุคคล หรือบางครั้งก็หมายความว่าปรับแต่งเอง เพื่อให้เหมาะสมและสอดคล้องกับกายวิภาคของผู้ป่วยแต่ละราย Conformis นำเสนอผลิตภัณฑ์ปลูกถ่ายข้อเข่าและสะโพกเฉพาะบุคคลและผลิตภัณฑ์ปลูกถ่ายแบบมาตรฐานหลากหลายที่ปลอดเชื้อ พร้อมด้วยเครื่องมือแบบใช้ครั้งเดียวที่ส่งไปยังโรงพยาบาลและศูนย์ศัลยกรรมผู้ป่วยนอก ในการศึกษาทางคลินิก ระบบการผ่าตัดเปลี่ยนข้อเข่าเทียม Conformis iTotal^® CR แสดงให้เห็นผลลัพธ์ทางคลินิกที่เหนือกว่า รวมถึงการทำงานที่ดีขึ้นและความพึงพอใจของผู้ป่วยมากกว่า เมื่อเทียบกับการปลูกถ่ายแบบดั้งเดิมที่มีจำหน่ายตามท้องตลาด Conformis เป็นเจ้าของหรือผู้ที่ได้รับสิทธิบัตรหรือการใช้งานที่อยู่ระหว่างการจดสิทธิบัตรที่รอดำเนินการ ซึ่งครอบคลุมการปลูกถ่ายส่วนบุคคลและเครื่องมือเฉพาะของผู้ป่วยสำหรับข้อต่อที่สำคัญทั้งหมด

สำหรับข้อมูลเพิ่มเติม โปรดไปที่ www.conformis.com หากต้องการรับการแจ้งเตือนทางอีเมลในอนาคต โปรดลงทะเบียนที่ http://ir.conformis.com

หมายเหตุข้อควรระวังเกี่ยวกับข้อความเชิงคาดการณ์เหตุการณ์ในอนาคต

ข้อความในข่าวประชาสัมพันธ์ฉบับนี้เกี่ยวกับความคาดหวัง แผนงาน และแนวโน้มในอนาคตของเรา ตลอดจนข้อความอื่นๆ ที่มีคำว่า “คาดการณ์”, “เชื่อ”, “ดำเนินการต่อ”, “สามารถ”, “ประมาณ”, “คาดว่า”, “ตั้งใจ”, “อาจจะ”, “อาจ”, “วางแผน”, “มีแนวโน้ม”, “คาดเดา”, “มีโครงการ”, “ควรจะ”, “เป้าหมาย”, “จะ” หรือ “น่าจะ” และสำนวนที่คล้ายคลึงกันถือเป็นข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตตามความหมายของบทบัญญัติการจำกัดความรับผิดชอบของกฎหมายปฏิรูปการฟ้องร้องคดีหลักทรัพย์ส่วนบุคคลปี 1995 คุณไม่ควรเชื่อถือข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตมากเกินไป ผลลัพธ์ที่แท้จริงอาจแตกต่างอย่างมากจากการคาดการณ์ที่เปิดเผยในข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตที่เราทำอันเป็นผลมาจากความเสี่ยงและความไม่แน่นอนต่างๆ รวมถึงความเสี่ยงและความไม่แน่นอนที่อธิบายไว้ในส่วน “ปัจจัยเสี่ยง” ของเอกสารที่ยื่นต่อสาธารณะของเรากับสำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ นอกจากนี้ ข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตที่รวมอยู่ในข่าวประชาสัมพันธ์ฉบับนี้แสดงถึงมุมมองของเรา ณ วันที่ในที่นี้ เราคาดหวังว่าเหตุการณ์และการพัฒนาที่ตามมาอาจส่งผลให้มุมมองของเราเปลี่ยนแปลงได้ อย่างไรก็ตาม ในขณะที่เราอาจเลือกที่จะปรับปรุงข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตเหล่านี้ในบางจุดในอนาคต เราขอปฏิเสธภาระผูกพันใดๆ ที่จะต้องดำเนินการดังกล่าว ไม่ควรยึดถือข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตเหล่านี้ว่าเป็นการแสดงความเห็นของเรา ณ วันที่ใดๆ ต่อจากวันที่ในที่นี้

ที่มา: Conformis, Inc.

ติดต่อด้านสื่อ:
ข้อมูลติดต่อสำหรับนักลงทุนสัมพันธ์
ir@conformis.com
(781) 374-5598

TeraRecon Announces Dan McSweeney President

DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) — Advanced visualization and AI leader TeraRecon, a SymphonyAI company, today announced the appointment of Dan McSweeney as president. He will be responsible for continuing and expanding TeraRecon’s leadership in healthcare advanced visualization and enterprise AI.

“TeraRecon is known for its strong reputation as the leader in advanced visualization and AI innovation in healthcare,” said McSweeney. “We are reinvesting the benefits of that leadership into delivering further value for organizations by maintaining excellence in advanced visualization and clinical workflow applications, as well as implementing next-gen, AI-based technologies for superior outcomes for patients and communities.”

TeraRecon leads the medical advanced visualization and AI market with its flagship Intuition product, delivering real-time imaging decision support for radiology, cardiology, vascular surgery, and more. Intuition is the 3D imaging market share leader in the US and the 2021 KLAS category leader for advanced visualization.

“TeraRecon has a long history of innovation and delivering customer value. Dan will help TeraRecon build on this history by accelerating AI-driven visualization and clinical solutions,” said Romesh Wadhwani, chairman and founder of TeraRecon’s parent company, SymphonyAI. “Dan’s track record of creating and expanding value through continuous solution improvement and deployment will serve the TeraRecon team well. He understands the importance of driving down barriers to adoption by making AI solutions valuable, practical, and ubiquitous.”

McSweeney brings to TeraRecon more than 20 years of strategic healthcare experience, with a strong track record of customer-centric growth. He spent 18 years with GE Capital and GE Healthcare in multiple executive roles. Most recently, he was at Wolters Kluwer Health, where he led the company’s $500 million business in the Americas.

About TeraRecon: TeraRecon, a SymphonyAI business, is a leader in advanced imaging and visualization AI and clinical AI solutions with a mission to continuously redefine patient and healthcare. The flagship Intuition product is the 2021 KLAS category leader for advanced visualization and holds the number one market share in 3D imaging in the US. TeraRecon is continuing to innovate ahead of customer demand with sophisticated healthcare-focused AI platform solutions unlike any in the world today.

About SymphonyAI

SymphonyAI is building the leading enterprise AI company for digital transformation across the most important and resilient growth verticals, including life sciences, healthcare, retail, consumer packaged goods, financial services, manufacturing, and media. In each of these verticals, SAI businesses have many of the leading enterprises as clients. SAI is backed by a $1 billion commitment from Dr. Romesh Wadhwani, a successful entrepreneur and philanthropist. Since its founding in 2017, SymphonyAI has grown rapidly to over 2,200 talented leaders, data scientists, and other professionals.

For more information, visit www.terarecon.com or info@terarecon.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f634d796-76e4-4209-871b-ee8a912b4f69